Gary A. Levy
#161,268
Most Influential Person Now
Gary A. Levy's AcademicInfluence.com Rankings
Gary A. Levymedical Degrees
Medical
#3247
World Rank
#3707
Historical Rank
Gastroenterology
#82
World Rank
#84
Historical Rank
Gary A. Levyphilosophy Degrees
Philosophy
#9313
World Rank
#12852
Historical Rank
Logic
#6295
World Rank
#7803
Historical Rank
Download Badge
Medical Philosophy
Gary A. Levy's Degrees
- Doctorate Medicine University of California, San Francisco
- PhD Biochemistry University of California, San Francisco
Why Is Gary A. Levy Influential?
(Suggest an Edit or Addition)Gary A. Levy's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension (1995) (431)
- A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B (2001) (418)
- Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. (2003) (407)
- Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. (1998) (344)
- Multicenter study of lamivudine therapy for hepatitis B after liver transplantation (1999) (289)
- Cutting Edge: Cytokine-Dependent Abortion in CBA × DBA/2 Mice Is Mediated by the Procoagulant fgl2 Prothombinase (1998) (278)
- Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. (2002) (273)
- Self-renewing resident arterial macrophages arise from embryonic CX3CR1+ precursors and circulating monocytes immediately after birth (2015) (260)
- A randomized double‐blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients (2001) (256)
- Patient management by Neoral C2 monitoring: An international consensus statement1 (2002) (235)
- Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. (1999) (221)
- Syncytial giant-cell hepatitis. Sporadic hepatitis with distinctive pathological features, a severe clinical course, and paramyxoviral features. (1991) (203)
- Biliary Strictures in 130 Consecutive Right Lobe Living Donor Liver Transplant Recipients: Results of a Western Center (2007) (191)
- Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). (1999) (190)
- Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1 (2002) (187)
- The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. (2003) (178)
- Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. (1989) (160)
- Lymphocyte cooperation is required for amplification of macrophage procoagulant activity (1980) (160)
- Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice (1981) (154)
- MurineHepatitis Virus Strain 1 Produces a Clinically Relevant Model of Severe Acute Respiratory Syndrome in A/J Mice (2006) (145)
- Targeted Deletion of fgl2 Leads to Impaired Regulatory T Cell Activity and Development of Autoimmune Glomerulonephritis1 (2008) (141)
- Quality of life following transplantation of the heart, liver, and lungs. (1996) (139)
- Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12‐ and 36‐month results (2006) (139)
- Severe Acute Respiratory Syndrome (SARS) in a Liver Transplant Recipient and Guidelines for Donor SARS Screening (2003) (138)
- RESULTS OF LIS2T, A MULTICENTER, RANDOMIZED STUDY COMPARING CYCLOSPORINE MICROEMULSION WITH C2 MONITORING AND TACROLIMUS WITH C0 MONITORING IN DE NOVO LIVER TRANSPLANTATION (2004) (136)
- Clinical validation studies of neoral C2 monitoring: a review (2002) (136)
- Soluble Fibrinogen-Like Protein 2/Fibroleukin Exhibits Immunosuppressive Properties: Suppressing T Cell Proliferation and Inhibiting Maturation of Bone Marrow-Derived Dendritic Cells1 (2003) (135)
- Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients (2017) (126)
- Derivation of a risk index for the prediction of massive blood transfusion in liver transplantation (2006) (125)
- Versican 3′‐untranslated region (3′‐UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity (2013) (124)
- Making sense of regulatory T cell suppressive function. (2011) (121)
- Impact of Absorption Profiling on Efficacy and Safety of Cyclosporin Therapy in Transplant Recipients (2000) (119)
- Histopathology of cocaine hepatotoxicity. Report of four patients. (1990) (116)
- Antiviral Treatment of Recurrent Hepatitis C After Liver Transplantation: Predictors of Response and Long-Term Outcome (2009) (116)
- Community-acquired West Nile virus infection in solid-organ transplant recipients (2004) (114)
- Clinical impact of human herpesvirus 6 infection after liver transplantation. (2002) (111)
- Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. (1998) (110)
- 16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. (1987) (110)
- Normothermic Acellular Ex Vivo Liver Perfusion Reduces Liver and Bile Duct Injury of Pig Livers Retrieved After Cardiac Death (2013) (108)
- Human herpesvirus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. (2000) (107)
- A graft to body weight ratio less than 0.8 does not exclude adult‐to‐adult right‐lobe living donor liver transplantation (2009) (103)
- Fgl2 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2. (2001) (103)
- 12‐month follow‐up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus (2006) (102)
- Interactions Between Cytomegalovirus, Human Herpesvirus‐6, and the Recurrence of Hepatitis C After Liver Transplantation (2002) (98)
- Endothelial Induction of fgl2 Contributes to Thrombosis during Acute Vascular Xenograft Rejection1 (2004) (98)
- Neoral absorption profiling: an evolution in effectiveness. (2000) (95)
- PROLONGATION OF RAT SMALL BOWEL OR RENAL ALLOGRAFT SURVIVAL BY PRETRANSPLANT TRANSFUSION AND/OR BY VARYING THE ROUTE OF ALLOGRAFT VENOUS DRAINAGE (1994) (94)
- Murine lymphoid procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase (1982) (93)
- Live Donor Liver Transplantation in High MELD Score Recipients (2010) (93)
- Radiotherapy as a bridge to liver transplantation for hepatocellular carcinoma (2010) (92)
- Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. (1999) (92)
- Incentives for Organ Donation: Proposed Standards for an Internationally Acceptable System (2012) (92)
- Adult Living Liver Donors have Excellent Long‐Term Medical Outcomes: The University of Toronto Liver Transplant Experience (2010) (92)
- Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. (1990) (90)
- Adult Right‐Lobe Living Liver Donors: Quality of Life, Attitudes and Predictors of Donor Outcomes (2009) (90)
- Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. (1981) (86)
- The FGL2‐FcγRIIB pathway: A novel mechanism leading to immunosuppression (2008) (86)
- The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen‐like protein 2 contributes to the outcome of murine fulminant viral hepatitis (2009) (84)
- Hepatitis C–related cirrhosis: A predictor of diabetes after liver transplantation (2000) (84)
- The Emerging Role of Immunoregulation of Fibrinogen‐Related Procoagulant Fgl2 in the Success or Spontaneous Abortion of Early Pregnancy in Mice and Humans (1999) (83)
- PREDICTION OF THE OUTCOME OF TRANSPLANTATION IN MAN BY PLATELET ADHERENCE IN DONOR LIVER ALLOGRAFTS: EVIDENCE OF THE IMPORTANCE OF PREPRESERVATION INJURY (1993) (82)
- Living‐Donor Right Hepatectomy with or without Inclusion of Middle Hepatic Vein: Comparison of Morbidity and Outcome in 56 Patients (2004) (82)
- The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide. (1981) (79)
- Reduced Mortality with Right‐Lobe Living Donor Compared to Deceased‐Donor Liver Transplantation When Analyzed from the Time of Listing (2007) (79)
- Donor-specific factors predict graft function following liver transplantation. (1990) (79)
- Analysis and Outcomes of Right Lobe Hepatectomy in 101 Consecutive Living Donors (2005) (79)
- Lamivudine for hepatitis B in liver transplantation: a single-center experience. (2000) (78)
- Association of mouse fibrinogen-like protein with murine hepatitis virus-induced prothrombinase activity (1995) (77)
- Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection (1992) (76)
- Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: two procoagulant activities are produced by peripheral blood mononuclear cells. (1981) (74)
- Genomic characterization, localization, and functional expression of FGL2, the human gene encoding fibroleukin: a novel human procoagulant. (2001) (72)
- Kinetic Analysis of a Unique Direct Prothrombinase, fgl2, and Identification of a Serine Residue Critical for the Prothrombinase Activity1 (2002) (71)
- Generic Immunosuppression in Solid Organ Transplantation: A Canadian Perspective (2012) (70)
- 2007 Update on Allogeneic Islet Transplantation from the Collaborative Islet Transplant Registry (CITR) (2009) (69)
- Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: Comparable survival and recurrence (2012) (69)
- Targeted Deletion of Fgl-2/Fibroleukin in the Donor Modulates Immunologic Response and Acute Vascular Rejection in Cardiac Xenografts (2005) (69)
- Ecology of Danger‐dependent Cytokine‐boosted Spontaneous Abortion in the CBA × DBA/2 Mouse Model. I. Synergistic Effect of LPS and (TNF‐α + IFN‐γ) on Pregnancy Loss (2004) (68)
- SMALL INTESTINAL TRANSPLANTATION USING CYCLOSPORINE: REPORT OF A CASE (1986) (68)
- Living donor versus deceased donor liver transplantation: a surgeon‐matched comparison of recipient morbidity and outcomes (2013) (67)
- Role of Fibrinogen-Like Protein 2 Prothrombinase/Fibroleukin in Experimental and Human Allograft Rejection1 (2005) (65)
- The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age (2008) (64)
- Effect of intraportal glucose infusion on hepatic glycogen content and degradation, and outcome of liver transplantation. (1992) (64)
- Biochemical and Clinical Response of Fulminant Viral Hepatitis to Administration of Prostaglandin E (1989) (63)
- A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. (1996) (63)
- Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. (1999) (62)
- Susceptibility/resistance to mouse hepatitis virus strain 3 and macrophage procoagulant activity are genetically linked and controlled by two non-H-2-linked genes. (1986) (61)
- Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low‐dose calcineurin inhibitor regimens (2008) (60)
- Post-transplant recurrent hepatitis B viral liver disease. Viral-burden, steatoviral, and fibroviral hepatitis B. (1992) (58)
- Monoclonal antibody analysis of a unique macrophage procoagulant activity induced by murine hepatitis virus strain 3 infection. (1991) (58)
- The novel immunoregulatory molecule FGL2: a potential biomarker for severity of chronic hepatitis C virus infection. (2010) (58)
- Cytokine-Induced Hepatic Apoptosis Is Dependent on FGL2/Fibroleukin: The Role of Sp1/Sp3 and STAT1/PU.1 Composite cis Elements (2006) (57)
- Subnormothermic ex vivo liver perfusion reduces endothelial cell and bile duct injury after donation after cardiac death pig liver transplantation (2014) (57)
- Recipient age affects long‐term outcome and hepatitis C recurrence in old donor livers following transplantation (2009) (56)
- Activation of the Novel Prothrombinase, fgl2, as a Basis for the Pregnancy Complications Spontaneous Abortion and Pre‐eclampsia (2001) (56)
- Pharmacokinetics of a New Oral Formulation of Cyclosporine in Liver Transplant Recipients (1995) (55)
- The fgl2 prothrombinase/fibroleukin gene is required for lipopolysaccharide-triggered abortions and for normal mouse reproduction. (2004) (55)
- Induction of Prothrombinase fgl2 by the Nucleocapsid Protein of Virulent Mouse Hepatitis Virus Is Dependent on Host Hepatic Nuclear Factor-4α* (2003) (54)
- Does Microvascular Invasion Affect Outcomes After Liver Transplantation for HCC? A Histopathological Analysis of 155 Consecutive Explants (2007) (54)
- Fulminant viral hepatitis: molecular and cellular basis, and clinical implications (2001) (53)
- Improvement in human decay accelerating factor transgenic porcine kidney xenograft rejection with intravenous administration of gas914, a polymeric form of &agr;gal1 (2003) (52)
- Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. (1996) (52)
- Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus. (1985) (52)
- Accuracy of Staging as a Predictor for Recurrence After Liver Transplantation for Hepatocellular Carcinoma (2006) (51)
- Hepatitis B Virus-induced hFGL2 Transcription Is Dependent on c-Ets-2 and MAPK Signal Pathway* (2008) (50)
- Protective effects of long pentraxin PTX3 on lung injury in a severe acute respiratory syndrome model in mice (2012) (50)
- The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B (2001) (49)
- Fibrinogen-like protein 2 fibroleukin expression and its correlation with disease progression in murine hepatitis virus type 3-induced fulminant hepatitis and in patients with severe viral hepatitis B. (2005) (49)
- The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo. (1985) (48)
- ORIGINAL ARTICLE: LPS‐Induced Murine Abortions Require C5 but not C3, and are Prevented by Upregulating Expression of the CD200 Tolerance Signaling Molecule (2008) (47)
- EFFECT OF COLD PRESERVATION ON LYMPHOCYTE ADHERENCE IN THE PERFUSED RAT LIVER (1991) (47)
- Procoagulants in fetus rejection: the role of the OX-2 (CD200) tolerance signal. (2001) (47)
- IL-10 Induces Regulatory T Cell Apoptosis by Up-Regulation of the Membrane Form of TNF-α 1 (2004) (46)
- Anonymous Living Liver Donation: Donor Profiles and Outcomes (2010) (46)
- Cyclosporine neoral in liver transplant recipients. (1994) (46)
- Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infection. (1998) (45)
- The Effect of Mouse Hepatitis Virus Infection on the Microcirculation of the Liver (2007) (45)
- A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation. (1996) (45)
- FGL2/fibroleukin mediates hepatic reperfusion injury by induction of sinusoidal endothelial cell and hepatocyte apoptosis in mice. (2012) (44)
- Efficacy and safety of everolimus with reduced tacrolimus in living‐donor liver transplant recipients: 12‐month results of a randomized multicenter study (2018) (44)
- Identification of a novel biomarker gene set with sensitivity and specificity for distinguishing between allograft rejection and tolerance (2012) (44)
- Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients. (2001) (43)
- Evidence for epitope spreading and active suppression in skin graft tolerance after donor-specific transfusion. (1999) (43)
- Living donor hepatectomy: The importance of the residual liver volume (2011) (43)
- Induction of macrophage procoagulant activity by Bacteroides fragilis (1989) (43)
- Role of regulatory T cells in the promotion of transplant tolerance (2012) (41)
- Deletion of Fibrinogen-like Protein 2 (FGL-2), a Novel CD4+ CD25+ Treg Effector Molecule, Leads to Improved Control of Echinococcus multilocularis Infection in Mice (2015) (41)
- Living vs. Deceased Donor Liver Transplantation Provides Comparable Recovery of Renal Function in Patients With Hepatorenal Syndrome: A Matched Case–Control Study (2014) (40)
- Thrombogenicity of total parenteral nutrition solutions: II. Effect on induction of endothelial cell procoagulant activity. (1989) (40)
- Coronavirus MHV-3-Induced Apoptosis in Macrophages (1998) (40)
- GITR Intrinsically Sustains Early Type 1 and Late Follicular Helper CD4 T Cell Accumulation to Control a Chronic Viral Infection (2015) (39)
- Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus. (1998) (39)
- Dissociation between the immunosuppressive activity of cyclosporine derivatives and their effects on intracellular calcium signaling in mesangial cells. (1989) (39)
- Resistance to murine hepatitis virus strain 3 is dependent on production of nitric oxide. (1998) (37)
- Proteasome Inhibition In Vivo Promotes Survival in a Lethal Murine Model of Severe Acute Respiratory Syndrome (2010) (37)
- Correlation of peripheral blood lymphocyte and intragraft cytokine mRNA expression with rejection in orthotopic liver transplantation. (1996) (36)
- Domino liver transplantation for familial amyloid polyneuropathy. (1998) (35)
- Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. (1994) (34)
- Thrombogenicity of total parenteral nutrition solutions: I. Effect on induction of monocyte/macrophage procoagulant activity. (1989) (34)
- Living Anonymous Liver Donation: Case Report and Ethical Justification (2007) (34)
- Donor Outcomes in Anonymous Live Liver Donation. (2019) (34)
- Live Donor Liver Transplantation With Older (≥50 Years) Versus Younger (<50 Years) Donors: Does Age Matter? (2016) (34)
- LAMIVUDINE FOR HEPATITIS B IN LIVER TRANSPLANTATION (2000) (34)
- Dynamic Changes in Clinical Features and Cytokine/Chemokine Responses in Sars Patients Treated with Interferon Alfacon-1 plus Corticosteroids (2005) (33)
- Intraoperative ‘No Go’ Donor Hepatectomies in Living Donor Liver Transplantation (2010) (33)
- Gene transcription of fgl2 in endothelial cells is controlled by Ets-1 and Oct-1 and requires the presence of both Sp1 and Sp3. (2003) (33)
- Immune complex-induced human monocyte procoagulant activity. II. Cellular kinetics and metabolic requirements. (1982) (32)
- Liver transplantation for acute and subacute fulminant hepatic failure. (1989) (32)
- Consensus on Neoral C(2) Expert Review in Transplantation (CONCERT) Group. Patient management by Neoral C(2) monitoring : an international consensus statement (2002) (31)
- C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral® Formulation (2012) (31)
- Acute pancreatitis following liver transplantation. (1995) (30)
- Liver transplantation in patients with end‐stage liver disease requiring intensive care unit admission and intubation (2015) (29)
- Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. (2006) (29)
- Surgical Complications after Right Hepatectomy for Live Liver Donation: Largest Single-Center Western World Experience (2018) (29)
- Excess zinc associated with severe progressive cholestasis in Cree and Ojibwa-Cree children (1996) (28)
- Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation. (1994) (28)
- Corona- and Related Viruses (2012) (28)
- Live Donor Liver Transplantation: A Valid Alternative for Critically Ill Patients Suffering From Acute Liver Failure (2015) (28)
- Potential for CsA-Neoral in organ transplantation. (1994) (28)
- Isoniazid prophylaxis in lung transplantation. (2000) (28)
- Treatment with Optifast reduces hepatic steatosis and increases candidacy rates for living donor liver transplantation (2016) (27)
- MONOCYTE PROCOAGULANT ACTIVITY AND PLASMINOGEN ACTIVATOR: ROLE IN HUMAN RENAL ALLOGRAFT REJECTION (1985) (27)
- IMPROVED CLINICAL OUTCOMES FOR LIVER TRANSPLANT RECIPIENTS USING CYCLOSPORINE BLOOD LEVEL MONITORING BASED ON TWO‐HOUR POST‐DOSE LEVELS.: Abstract# 1059 (2000) (26)
- Resistance to Murine Hepatitis Virus Strain 3 Is Dependent on Production of Nitric Oxide (1998) (26)
- Severe acute respiratory syndrome and the liver (2004) (26)
- Donor BMI >30 Is Not a Contraindication for Live Liver Donation (2017) (26)
- A role for gamma(delta)TCR+ cells in regulation of rejection of small intestinal allografts in rats. (1996) (26)
- Artificial liver support--pipe dream or reality? (1994) (26)
- The vascular pathology of human hepatic allografts. (1993) (26)
- Erratum: Safety, tolerability, and efficacy of everolimus in De Novo liver transplant recipients: 12- and 36-month results (Liver Transplantation (2006) vol. 12 (1640-1648)) (2006) (26)
- The immunosuppressive pipeline: Meeting unmet needs in liver transplantation (2010) (25)
- Neoral C2 in liver transplant recipients (2001) (25)
- Relationship of pharmacokinetics to clinical outcomes. (1999) (25)
- Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and Neoral in liver transplant recipients. Ontario Liver Transplant Study Group. (1996) (24)
- Selective Use of Older Adults in Right Lobe Living Donor Liver Transplantation (2007) (24)
- Neoral therapy in liver transplantation. (1996) (24)
- Loss of resistance to murine hepatitis virus strain 3 infection after treatment with corticosteroids is associated with induction of macrophage procoagulant activity (1996) (23)
- Characterization of fibrinogen-like protein 2 (FGL2): monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2. (2013) (23)
- Manipulation of skin graft rejection in alloimmune mice by anti-VCAM-1:VLA-4 but not anti-ICAM-1:LFA-1 monoclonal antibodies. (1995) (23)
- Right lobe living-donor hepatectomy-the Toronto approach, tips and tricks. (2016) (23)
- Fgl2 deficiency causes neonatal death and cardiac dysfunction during embryonic and postnatal development in mice. (2007) (22)
- Long‐term immunosuppression and drug interactions (2001) (22)
- Genetic Determinants of Mouse Hepatitis Virus Strain 1 Pneumovirulence (2010) (22)
- Disparate mechanisms of induction of procoagulant activity by live and inactivated bacteria and viruses (1990) (22)
- Adult-to-adult living donor liver transplantation. (2006) (21)
- The pathobiology of viral hepatitis and immunologic activation of the coagulation protease network. (1984) (21)
- Immune responses in small intestinal transplantation in the rat: correlation of histopathology and monocyte procoagulant activity. (1987) (20)
- Cosmesis and Body Image After Adult Right Lobe Living Liver Donation (2010) (20)
- Small encapsulated hepatocellular carcinoma of the liver provisional analysis of pathogenetic mechanisms (1993) (20)
- Fostering liver living donor liver transplantation (2016) (20)
- Targeted Deletion of FGL2 Leads to Increased Early Viral Replication and Enhanced Adaptive Immunity in a Murine Model of Acute Viral Hepatitis Caused by LCMV WE (2013) (20)
- Procoagulant activity in gastroenterology. (1990) (19)
- Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C (1999) (19)
- THE EFFECTS OF 16, 16 DIMETHYL PROSTAGLANDIN E2 THERAPY ALONE AND IN COMBINATION WITH LOW‐DOSE CYCLOSPORINE ON RAT SMALL INTESTINAL TRANSPLANTATION (1992) (19)
- Prostaglandins in liver failure and transplantation: regeneration, immunomodulation, and cytoprotection. Prostaglandins in Liver Transplantation Research Group. (1996) (19)
- CD4(-)CD8(-) regulatory T cells implicated in preventing graft-versus-host and promoting graft-versus-leukemia responses. (2001) (18)
- STAT1 and STAT3 α/β splice form activation predicts host responses in mouse hepatitis virus type 3 infection (2003) (18)
- Improvement in rejection of human decay accelerating factor transgenic pig-to-primate renal xenografts with administration of rabbit antithymocyte serum1 (2002) (18)
- Ancrod improves survival in murine systemic lupus erythematosus. (1990) (18)
- Protein Interferon-Stimulated Gene 15 Conjugation Delays but Does Not Overcome Coronavirus Proliferation in a Model of Fulminant Hepatitis (2014) (18)
- Cellular pathways and signals for the induction of biosynthesis of initiators of the coagulation protease cascade by cells of the monocyte lineage (1985) (18)
- Expression of macrophage procoagulant activity in murine systemic lupus erythematosus. (1986) (17)
- The major histocompatibility complex requirement for cellular collaboration in the murine lymphoid procoagulant response stimulated by bacterial lipopolysaccharide. (1982) (17)
- Activation of the Immune Coagulation System by Murine Hepatitis Virus Strain 3 (1989) (17)
- Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation (2005) (17)
- Coagulation factors as indicators of early graft function following liver transplantation. (1989) (17)
- Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine. (1997) (17)
- The Role of FGL2 in the Pathogenesis and Treatment of Hepatitis C Virus Infection (2010) (16)
- Evaluation of liver transplantation for high‐risk indications (1997) (16)
- Predictors of graft function following liver transplantation. (1989) (16)
- A Th1 cell line (3E9.1) from resistant A/J mice inhibits induction of macrophage procoagulant activity in vitro and protects against MHV-3 mortality in vivo. (1994) (16)
- Financial, vocational, and interpersonal impact of living liver donation (2009) (16)
- Comparison of the long-term tolerability, pharmacodynamics, and safety of Sandimmune and neoral in liver transplant recipients (1996) (16)
- Lymphocyte-instructed monocyte induction of the coagulation pathways parallels the induction of hepatitis by the murine hepatitis virus. (1982) (16)
- Role of Regulatory T Cells (Treg) and the Treg Effector Molecule Fibrinogen-like Protein 2 in Alloimmunity and Autoimmunity (2015) (16)
- REFINE: A Randomized Trial Comparing Cyclosporine A and Tacrolimus on Fibrosis After Liver Transplantation for Hepatitis C (2014) (16)
- hDAF transgenic pig livers are protected from hyperacute rejection during ex vivo perfusion with human blood (2002) (15)
- Treatment of fulminant viral hepatic failure with prostaglandin E (1991) (15)
- Murine Hepatitis Virus Strain 1 as a Model for Severe Acute Respiratory Distress Syndrome (Sars) (2006) (15)
- Neoral in liver transplantation. (1996) (15)
- Cigarette smoking—association with hepatic artery thrombosis (2002) (15)
- Prostaglandin E2 prevents fulminant hepatitis and the induction of procoagulant activity in susceptible animals. (1987) (14)
- STAT1 and STAT3 alpha/beta splice form activation predicts host responses in mouse hepatitis virus type 3 infection. (2003) (14)
- Overexpression of Fibrinogen‐Like Protein 2 Promotes Tolerance in a Fully Mismatched Murine Model of Heart Transplantation (2016) (14)
- Graft-infiltrating cells in rats receiving orthotopic semiallogeneic small intestine transplantation with portal or systemic venous drainage. (1996) (14)
- Relevance of hepatitis B viral DNA in assessment of potential liver allograft recipients. (1989) (14)
- Mouse hepatitis virus-3 induced prothrombinase (Fgl2) maps to proximal chromosome 5. (1995) (14)
- Toxic effects on renal cells in culture--a comparison of cyclosporin A and its metabolites. (1989) (14)
- Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor (2013) (13)
- Neoral use in the liver transplant recipient. (2000) (13)
- Cellular and metabolic requirements for induction of macrophage procoagulant activity by murine hepatitis virus strain 3 in vitro. (1991) (13)
- Induction of T-cell hyporesponsiveness by intrahepatic modulation of donor antigen-presenting cells. (1995) (13)
- Susceptibility to mouse hepatitis virus strain 3 in BALB/cJ mice: failure of immune cell proliferation and interleukin 2 production. (1987) (13)
- Surgical revision of biliary strictures following adult live donor liver transplantation: patient selection, morbidity, and outcomes (2012) (13)
- Acute Liver Failure: Role of cytokines and immune mechanisms in acute liver failure (1996) (12)
- Neoral is superior to FK 506 in liver transplantation. (1998) (12)
- Generation of Antigen Microarrays to Screen for Autoantibodies in Heart Failure and Heart Transplantation (2016) (12)
- The immune response to mouse hepatitis virus: genetic variation in antibody response and disease. (1984) (12)
- Regulatory roles of T mu and T gamma cells in the collaborative cellular initiation of the extrinsic coagulation pathway by bacterial lipopolysaccharide. (1985) (12)
- Corona- and related viruses : current concepts in molecular biology and pathogenesis (1995) (12)
- High preoperative bilirubin values protect against reperfusion injury after live donor liver transplantation (2015) (11)
- Inhibition of the Fibrinogen‐Like Protein 2:FcγRIIB/RIII immunosuppressive pathway enhances antiviral T‐cell and B‐cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13 (2018) (11)
- Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials (2020) (11)
- Immunosuppression in liver transplantation. (2000) (11)
- Mechanism of protective effect of prostaglandin E in murine hepatitis virus strain 3 infection: effects on macrophage production of tumour necrosis factor, procoagulant activity and leukotriene B4. (1990) (10)
- Hepatic regulation of lymphocyte adhesion to, and activation on, syngeneic endothelial monolayers. (1994) (10)
- Kupffer cell erythrophagocytosis and graft-versus-host hemolysis in liver transplantation. (1996) (10)
- The alpha-Gal analog GAS914 ameliorates delayed rejection of hDAF transgenic pig-to-baboon renal xenografts. (2001) (10)
- Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C. (2012) (10)
- Recipient factors associated with having a potential living donor for liver transplantation (2015) (10)
- Cyclosporin A metabolites suppress T-cell proliferation by concanavalin A and in a mixed lymphocyte reaction. (1988) (10)
- Advances in transplantation. (2011) (9)
- Production But Inhibits Th2 Cytokine Response Prothrombinase and Preserves Th1 Cytokine Production of TNF, IL-1, the Procoagulant fgl2 Ribavirin Inhibits Viral-Induced Macrophage (1998) (9)
- Identification of the Receptor for FGL2 and Implications for Susceptibility to Mouse Hepatitis Virus (MHV-3)-Induced Fulminant Hepatitis (2006) (9)
- Long-term ribavirin therapy for recurrent hepatitis C after liver transplantation. (1997) (9)
- Avoiding ICU Admission by Using a Fast-Track Protocol Is Safe in Selected Adult-to-Adult Live Donor Liver Transplant Recipients (2017) (9)
- Effect of eicosanoids on induction of procoagulant activity by murine hepatitis virus strain 3 in vitro. (1991) (9)
- Cyclosporine A in contrast to a cyclosporine metabolite (OL-17) specifically inhibits growth of renal cells in culture. (1988) (9)
- Identification of cyclosporine metabolites in human bile, blood, and urine by high-performance liquid chromatography/radioimmunoassay/fast atomic bombardment mass spectroscopy. (1988) (9)
- DEPRESSION, QUALITY OF LIFE, AND LIVER TRANSPLANTATION (1999) (8)
- Cyclosporine pharmacokinetics and blood pressure responses after conversion to once‐daily dosing in maintenance liver transplant patients (2007) (8)
- Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis (2017) (8)
- Sera from habitual aborters induce monocyte procoagulant activity: a lymphocyte-dependent event. (1994) (8)
- Lymphoid procoagulant activity and mitogenesis in the C3H/HeJ mouse: discordant response to lipopolysaccharide stimulation. (1980) (8)
- Clinical Utility Of Cytomegalovirus (CMV) Viral Load Determination For Predicting CMV Disease In Liver Transplant Recipients (1999) (8)
- A 2',5'-oligoadenylate analogue inhibits murine hepatitis virus strain 3 (MHV-3) replication in vitro but does not reduce MHV-3-related mortality or induction of procoagulant activity in susceptible mice. (1995) (7)
- Immune responses during small-intestinal allograft rejection: correlation between procoagulant activity and histopathology. (1990) (7)
- Cyclosporine metabolites suppress T cell proliferation induced by concanavalin A. (1987) (7)
- The comparative effects of cyclosporin A and 16,16 dimethyl prostaglandin E2 on the allogeneic induction of monocyte/macrophage procoagulant activity and the cytokines macrophage procoagulant inducing factor and interleukin-2. (1991) (7)
- Progress in Transplantation (2010) (7)
- Post-Transplant Lymphoproliferative Disorder: Evaluation of Effectiveness of Reduction of Immunosuppression or Systemic Chemotherapy (2008) (7)
- Generation of Two-color Antigen Microarrays for the Simultaneous Detection of IgG and IgM Autoantibodies. (2016) (7)
- Characterization of immune responses in different lymphoid compartments during small intestinal allograft rejection. (1990) (7)
- Late graft loss following liver transplantation. (1997) (6)
- The pattern of induction of apoptosis during infection with MHV-3 correlates with strain variation in resistance and susceptibility to lethal hepatitis. (1998) (6)
- Generation and characterization of cyclosporine metabolites produced in a hepatic microsomal system. (1988) (6)
- Fulminant Hepatic Failure in Murine Hepatitis Virus Strain 3 Infection : Tissue-Specific Expression of a Novel fgl 2 Prothrombinase (1997) (6)
- Hepatic mononuclear cells modulate delivery of immunogenic stimuli by allogeneic dendritic cells. (1999) (6)
- Renal Function Outcomes with Everolimus Plus Reduced-Exposure Tacrolimus in de Novo Living Donor Liver Transplantation: 24-month results from the H2307 study (2018) (6)
- Neoral without intravenous cyclosporine in liver transplantation. (1997) (6)
- A pharmacoeconomic analysis of Neoral without intravenous cyclosporine in liver transplantation in Canada. (1998) (6)
- Induction of macrophage procoagulant activity by murine hepatitis virus strain 3: role of tyrosine phosphorylation (1995) (6)
- MHV-3 induced prothrombinase is encoded by musfiblp. (1995) (5)
- MONOCYTE/MACROPHAGE PROCOAGULANT ACTIVITY AS A MEASURE OF IMMUNE RESPONSIVENESS IN LEWIS AND BROWN NORWAY INBRED RATS (1989) (5)
- Neoral C(2) in liver transplant recipients. (2001) (5)
- Deletion of fibrinogen-like protein 2, a novel CD4+ CD25+ Treg effector molecule, leads to improved control of Echinococcus mutilocularis infection (MPF7P.718) (2015) (5)
- ILLNESS INTRUSIVENESS & TRANSPLANTATION (1999) (5)
- Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection. (2015) (5)
- [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. (1998) (5)
- Gamma delta TCR+ cells regulate rejection of small intestinal allografts in rats. (1997) (5)
- Outcome of kidney transplantation alone versus synchronous pancreas-kidney transplantation in type 1 diabetics. (1998) (5)
- Domino liver transplantation for familial amyloid polyneuropathy: optimal use of a scarce resource (1999) (5)
- Strategies to prevent thrombosis in xenotransplants. (1998) (5)
- Sotrastaurin in Liver Transplantation: Has It Had a Fair Trial? (2015) (5)
- The present status of xenotransplantation. (2001) (4)
- The effects of mouse hepatitis virus type 3 on the microcirculation of the liver in inbred strains of mice. (1984) (4)
- Neoral C2 monitoring in solid organ transplantation. (2004) (4)
- Neoral/cyclosporine-based immunosuppression. (1999) (4)
- Antilymphoblast globulin (ALG) as initial prophylaxis against rejection following liver transplantation. (1989) (4)
- Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2, response, whereas pre-existing antibody partially protects against primary infection. (1998) (4)
- Treatment with rabbit antithymocyte serum permits a cyclophosphamide-free approach to prevention of hDAF transgenic porcine kidney xenograft rejection in baboons. (2001) (4)
- Treatment of resistant A/J mice with methylprednisolone (MP) results in loss of resistance to murine hepatitis strain 3 (MHV-3) and induction of macrophage procoagulant activity (PCA). (1995) (4)
- Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral. (1998) (4)
- New Therapeutic Strategies for Chronic Hepatitis (1992) (4)
- Should We Exclude Live Donor Liver Transplantation for Liver Transplant Recipients Requiring Mechanical Ventilation and Intensive Care Unit Care? (2015) (4)
- Domino liver transplantation for familial amyloid polyneuropathy: optimal use of a scarce resource. (1998) (4)
- Ex vivo and extracorporeal perfusion with hDAF pig kidneys * (2003) (4)
- Natural history of recurrent hepatitis C after liver transplantation. (2001) (4)
- Neoral C2 monitoring in maintenance liver transplant patients: A step forward? (2004) (4)
- Cyclosporine: role of pharmacokinetics (2001) (3)
- Migration patterns of lymphocytes following syngeneic heterotopic small bowel transplantation in rodents. (1993) (3)
- The University of Toronto liver transplant program. (1996) (3)
- EFFICACY OF MYCOPHENOLATE MOFETIL (MMF) IN LIVER TRANSPLANT RECIPIENTS: RESULTS OF A RANDOMIZED DOUBLE BLIND COMPARATIVE STUDY WITH AN ANALYSIS OF THE IMPACT OF HEPATITIS C.: Abstract# 27 (2000) (3)
- Effect of DRw6 antigen in recipients and donors on survival after liver transplant. (1989) (3)
- Monocyte procoagulant activity in Whipple's disease (1984) (3)
- Pretreatment of donor stimulator cells by 16,16 dimethyl prostaglandin E2 influences the recipient immune response. (1998) (3)
- Immunologic basis of small intestinal allograft rejection. (1991) (3)
- Incidence and patterns of rejection using different induction therapies in liver transplant recipients. (1994) (3)
- Gamma delta TCR+, type-2 cytokine produced by hybridoma cells produced in mice given portal vein pretransplant immunization and allogeneic grafts can increase graft survival on adoptive transfer. (1997) (3)
- Altered cell trafficking of mesenteric lymphocytes after heterotopic small bowel transplantation using systemic venous drainage. (1993) (3)
- Cyclosporine A vs cyclosporine A metabolites: comparisons of in vivo and in vitro immunosuppressive and toxic effects. (1990) (3)
- Altered serum cytokines in hepatic and portal blood of rats at early times following portal venous infusion of semi-allogeneic cells. (1996) (3)
- New strategies to optimize clinical outcomes with cyclosporine in liver transplantation. (2002) (3)
- Clinical small intestinal transplantation using cyclosporine A and methylprednisolone. (1987) (2)
- RIBAVIRIN TREATMENT OF RECURRENT HEPATITIS C VIRUS (HCV) FOLLOWING LIVER TRANSPLANTATION: PROPOSED MECHANISM OF ACTION. (1998) (2)
- [The study of cis-element HNF4 in the regulation of mfg12 prothrombinase/fibroleukin gene expression in response to nucleocapsid protein of MHV-3]. (2003) (2)
- Effect of alterations in early signal transduction events on the induction of procoagulant activity by murine hepatitis virus strain 3 in vitro. (1995) (2)
- Live donor liver transplantation with older donors: Increased long‐term graft loss due to HCV recurrence (2018) (2)
- Prostaglandin E2 (PGE2) alters the pathogenesis of MHV-3 infection in susceptible BALB/cJ mice. (1987) (2)
- A first-in-class therapy for the treatment of advanced stage liver cancer. (2016) (2)
- 168 HIGH RATES OF UNDETECTABLE HCVRNA IN LIVER TRANSPLANT RECIPIENTS TREATED WITH PROTEASE INHIBITOR-BASED ANTIVIRAL THERAPY FOR RECURRENT HEPATITIS C (2013) (2)
- Introduction. Neoral use in organ transplantation. (2000) (2)
- Balancing cyclosporine A nephrotoxicity and rejection late after adult liver transplantation. (1993) (2)
- STAT1 and STAT3 alpha/beta splice form activation predicts host responses in mouse hepatitis virus type 2 infection. J Med Virol 2003;69:306-312. (2003) (2)
- Case study: conversion of a liver transplant patient from cyclosporine Sandimmune to Neoral. (1996) (2)
- Early cellular events in the induction of murine hepatitis virus (MHV-3) induced macrophage procoagulant activity (PCA). (1993) (2)
- A proposed role for the immune system in the pathogenesis of hepatitis B virus induced liver disease. (1981) (2)
- Cyclosporine Neoral in liver transplant recipients. (1994) (2)
- The Existence Of T Helper (Tμ) And T Suppressor (Tγ) Cells For The Generation Of Monocyte Thromboplastin Activity By Lipopolysaccharides (1981) (1)
- Role of macrophage procoagulant activity in mouse hepatitis virus (MHV) infection: studies using T cell MHV-3 clones and monoclonal antibody 3D4.3. (1993) (1)
- Evaluation of a gene expression biomarker to identify operationally tolerant liver transplant recipients: the LITMUS trial (2021) (1)
- The TMC study (2003) (1)
- Identification of a unique glomerular factor X activator in murine lupus nephritis. (1999) (1)
- Hepatitis B Virus Proteins Induce Activation of hfgl2 Prothrombinase Gene Through c-Ets-2 Transcription Factors (2007) (1)
- REPORT OF THE ORGAN AND TISSUE TRANSPLANTATION WAIT TIMES EXPERT PANEL (2009) (1)
- Perioperative Management of the Liver Transplant Patient (1990) (1)
- 626 ASSESSMENT OF RESPONSE TO SORAFENIB IN HEPATOCELLULAR CARCINOMA: PROGNOSTIC VALUE OF TUMORAL DENSITY AND ARTERIAL ENHANCEMENT MEASUREMENTS IN TARGET LESIONS (2011) (1)
- Measurements of serial plasma levels of albumin mRNA for management of patients post transplant: does it add value? (2013) (1)
- INFECTIOUS COMPLICATIONS IN LIVER TRANSPLANT RECIPIENTS TRANSPLANTED FOR HEPATITIS C.: Abstract# 603 (2000) (1)
- Anonymous live liver donation: Outcomes of 50 cases (2018) (1)
- Genetic Predisposition To The Expression Of Lymphoid Procoagulant Activity (PCA) In Response To Viral Stimulation (1981) (1)
- Theimunopathogenesis of cronic HBV inducedliver disease (1981) (1)
- Induction of a procoagulant monokine is a marker for susceptibility to murine viral hepatitis. Abstr. (1981) (1)
- The reversal of cyclosporin A mediated suppression of allogeneic-induced monocyte procoagulant activity by H2 antagonist in a rat small intestinal transplantation model. (1989) (1)
- Not TH1 nor TH2 but 'danger' for whom the belle tolls (2002) (1)
- Functional activity in host and graft lymphoid tissue of rats receiving syngeneic heterotopic small bowel transplants with portal or systemic drainage. (1993) (1)
- Comparison of functional activity in host and graft mesenteric lymphoid tissue of rats receiving syngeneic heterotopic small bowel allografts with portal or systemic drainage. (1992) (1)
- Hepatotoxicity of Immunomodulating Agents (1996) (1)
- The reversal of cyclosporin A-mediated suppression of allogeneic induced monocyte procoagulant activity by H2 antagonists in-vitro. (1989) (1)
- Altered cell trafficking in mesenteric lymphoid tissue following syngeneic heterotopic small bowel transplantation in rodents. (1992) (0)
- THYMOGLOBULIN SIGNIFICANTLY REDUCES THE RISK OF ACUTE REJECTION IN RIGHT LOBE LIVING-DONOR LIVER TRANSPLANT (LDLT) RECIPIENTS (2004) (0)
- Hepatitis C virus (2015) (0)
- Model of Fulminant Hepatitis Overcome Coronavirus Proliferation in a Conjugation Delays but Does Not Protein Interferon-Stimulated Gene 15 (2014) (0)
- From DISCOVERY to CURE Hepatitis C Virus (2013) (0)
- Sustained Virological Response With Cyclosporine and Tacrolimus in Maintenance Liver Transplant Recipients With Recurrent Hepatitis C: Results From the SUSTAIN Study.: Abstract# A425 (2014) (0)
- Identification of cyclosporine metabolites in human bile, blood and urine by HLPC/RIA/FABMS (1987) (0)
- A DOUBLE-BLIND RANDOMIZED TRIAL OF A PRIMING STRATEGY USING PNEUMOCOCCAL CONJUGATE VACCINE IN ADULT LIVER TRANSPLANT RECIPIENTS. (2006) (0)
- Letter to the Editor (2003) (0)
- OUTCOME OF 100 CONSECUTIVE PATIENTS WITH CHRONIC HEPATITIS B TRANSPLANTED IN A SINGLE CENTER: EFFICACY OF SHORT-TERM, LOW DOSE HBIG + LAMIVUDINE (LAM) IN PREVENTING DISEASE RECURRENCE: 1262 (2008) (0)
- Procoagulant Activity in Health and Disease (2019) (0)
- A QUANTITATIVE PROTEOMICS APPROACH FOR IDENTIFICATION OF POTENTIAL BIOMARKERS IN TRANSPLANT TOLERANCE: 2584 (2010) (0)
- 102Improved clinical outcomes for liver transplant recipients using cyclosporin blood level monitoring two hours post dosage (2000) (0)
- BILIARY STRICTURES IN 130 CONSECUTIVE RIGHT LOBE LIVING DONOR LIVER TRANSPLANT RECIPIENTS AND MANAGEMENT. (2006) (0)
- Live Donor Liver Transplantation Provides Similar Outcome Compared to Full Graft Liver Transplantation in Patients With Hepatorenal Syndrome.: Abstract# 1484 (2014) (0)
- Resistance to murine hepatitis virus strain 3 (MHV-3) infection in A/J mice is not affected by cyclosporin A (CsA). (1987) (0)
- GITR-/- mice have defective follicular helper CD4 T cell responses following LCMV cl 13 infection. (2015) (0)
- Graft-infiltrating cells in small intestinal transplants of rats with portal or inferior vena cava drainage. (1994) (0)
- FGL2 EXPRESSION INDUCES GRAFT SURVIVAL IN THE ABSENCE OF IMMUNOSUPPRESSION: 2066 (2010) (0)
- INDUCED CD4+CD25+FOXP3+ REGULATORY T CELLS AND IMPAIRED DEVELOPMENT OF CD8+CD44+CD62L+ MEMORY T CELLS PROMOTE SPECIFIC TOLERANCE TO CARDIAC ALLOGRAFTS FOLLOWING RAPAMYCIN TREATMENT: 1859 (2010) (0)
- Characterization of the procoagulant-inducing factor derived from the plasma of BXSB mice. (1995) (0)
- Organ transplantation (PP-076) (2010) (0)
- 310 Ribavirin coupled to hemoglobin protects against viral hepatitis induced by the corona virus MHV-3 in mice (2003) (0)
- Biomarkers for early detection of post-transplantation rejection. (2011) (0)
- The co-stimulatory molecule GITR intrinsically enhances type 1 and follicular helper CD4 T cell responses to establish early control of a persistent viral infection and potentiate the late humoral response (IRC9P.700) (2014) (0)
- Autoantibodies (Non-MHC Antibodies) in a Mouse Model of Chronic Rejection: Profiling By Antigen Microarrays (2015) (0)
- plasma Levels Of Fibrinogen Like Protein 2: A Novel Tool For Monitoring Responses To Antiviral Therapy In Chronic Hcv Patients : 1052 (2010) (0)
- Everolimus with reduced tacrolimus versus standard tacrolimus in living-donor liver transplant recipients: Baseline data from the H2307 Study (2015) (0)
- FGL2/FIBROLEUKIN MEDIATES HEPATIC REPERFUSION INJURY BY INDUCTION OF SINUSOIDAL ENDOTHELIAL CELL APOPTOSIS IN MICE: 758 (2010) (0)
- Marrow-Derived Dendritic Cells and Inhibiting Maturation of Bone Properties : Suppressing T Cell Proliferation 2 / Fibroleukin Exhibits Immunosuppressive Soluble Fibrinogen-Like Protein and (2003) (0)
- ABSORPTION PROFILE OF RAD IN DE NOVO LIVER TRANSPLANT PATIENTS (1999) (0)
- 288 Non-HLA Antibodies and Risk of Rejection after Heart Transplantation: Profiling with Antigen Microarrays (2012) (0)
- Rapamycin promotes tolerance through increased expression of CD4+CD25+Foxp3+ regulatory T cells and impaired development of CD8+CD44+CD62L+ memory T cells. (145.25) (2010) (0)
- Surgical Biology for the Clinician Biologie chirurgicale pour le clinicien (1999) (0)
- Peri operative Management of the Liver Transplant Patient (1990) (0)
- Rejection XenograftThrombosis during Acute Vascular Endothelial Induction of fgl 2 Contributes to (2004) (0)
- The effects of 16,16-dimethyl prostaglandin E2 therapy alone and in combination with low-dose cyclosporine on rat small intestinal transplantation. (1992) (0)
- 97 Non-HLA Antibodies in Heart Transplant Recipients with AMR: Profiling with Antigen Microarrays (2012) (0)
- Use of Antigen Microarrays To Detect Non-HLA Antibodies in Patients with Heart Transplant Rejection (2011) (0)
- Measurement of AM19 and Other Cyclosporine Metabolites in the Blood of Liver Transplant Patients with Stable Liver Function (1995) (0)
- Pathways for Induction and The Nature of Macrophage Procoagulant Activity (2019) (0)
- Is absorption of cyclosporine microemulsion similar after cadaveric and living donation liver transplantation (2004) (0)
- Procoagulant fgl 2 Prothombinase CBA × DBA / 2 Mice Is Mediated by the Cutting Edge : Cytokine-Dependent Abortion in Mittruecker and (1998) (0)
- Normothermic Acellular Ex Vivo Liver Perfusion (NEVLP): Development of a New Method for the Storage, Assessment, and Repair of Marginal Liver Grafts: 1713 (2012) (0)
- Prognosis, Prevention and Research Prospects of Progression to Severe Hepatitis B (Liver Failure) (2019) (0)
- Over-expression of FGL2 leads to indefinite graft survival without the need for immunosuppression. (145.37) (2010) (0)
- Fulminant hepatitis (2004) (0)
- Efficacy and Safety of Everolimus With Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplant: Design of a Randomized Study.: Abstract# D2591 (2014) (0)
- PHARMACOKINETICS AND TOLERABILITY OF 40–0-[2-HYDROXYETHYL]RAPAMYCIN IN DE NOVO LIVER TRANSPLANT RECIPIENTS1 (2001) (0)
- Isolation and identification of two cyclosporine aldehydic metabolites from the bile of a liver transplant recipient during an acute nephrotoxic episode. (1994) (0)
- SARS, hepatitis and other coronavirus-related diseases and implications of a novel immunoregulatory prothrombinase, FGL2. (2005) (0)
- Can split liver grafting increase the overall success rate of liver transplantation? (1993) (0)
- Abstract 19631: The Immunoregulatory Protein FGL2 Extends Graft Survival in a Fully-Mismatched Cardiac Transplantation Model (2010) (0)
- Impact of Donor Age on Recurrence of Hepatitis C Following Living Donor and Deceased Donor Liver Transplantation (2007) (0)
- Acute Hepatic Failure: University of Toronto Experience (1993) (0)
- 789 Levels of Fgl2/Fibroleukin An Effector of CD4+Cd25+Treg Cells Predicts Course of Chronic Hepatitis C Disease (2008) (0)
- Abstract 18401: The Immunoregulatory Cytokine FGL2 is Associated With Functional Impairment in Patients With Heart Failure (2013) (0)
- Approach to the Patient with Severe Liver Failure (1991) (0)
- The University of Toronto Liver Transplant Program: Toronto General Hospital, Hospital for Sick Children. (2000) (0)
- Serine Residue Critical for the , and Identification of a fgl2 Prothrombinase, Kinetic Analysis of a Unique Direct (2017) (0)
- Hepatic regulation of lymphocyte-endothelial cell interaction. (1994) (0)
- IMPACT OF EXPERIENCE ON RISK OF BILIARY COMPLICATIONS IN LIVING-DONOR LIVER TRANSPLANTION (2004) (0)
- Progression of fibrosis in HCV+ liver transplant recipients treated with cyclosporine or tacrolimus (2013) (0)
- Lamivudine (3TC) for Hepatitis B in Liver Transplantation: The Toronto Hospital Experience. (1999) (0)
- NATURAL HISTORY OF RUCURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION.: Abstract# 772 Poster Board #‐Session: P29‐III (2000) (0)
- Cyclosporine A fails to alter innate host resistance to murine hepatitis virus strain 3 infection in A/J mice. (1987) (0)
- State of the art: coronaviruses (1995) (0)
- W1020 Outcome of Murine Hepatitis Virus Strain 3-Induced Fulminant Hepatitis Is Regulated By CD4+Cd25+ Treg Production of Fgl2 (2008) (0)
- A comparative analysis of the participation and knowledge gained by clinicians and researchers in a web based learning program on regenerative medicine (2015) (0)
- MONOCYTE PROCOAGULANT ACTIVITY BY MURINE HEPATITIS (2003) (0)
- Targeted deletion of fgl2 leads to enhanced anti-viral CD8 + T cell responses in the spleen of LCMV-infected mice. (2013) (0)
- The Role of Procoagulant Activity in Fulminant Viral Hepatitis (2019) (0)
- Optimizing the Use of Neoral in Liver and Kidney Transplantation by C2 Monitoring (2002) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Gary A. Levy?
Gary A. Levy is affiliated with the following schools:
